Novavax announces COVID-19 vaccine booster data indicating four-fold increase in neutralising antibodies
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Board declares interim dividend of Rs 2 per equity share
This work has been published in the journal ‘ACS applied materials and interface’
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Board approves fundraise of Rs 1500 crore
The company expects revenue growth of 10-15 per cent in the US
PAT rises to Rs 195.76 crore
The transaction is expected to close in the Q4FY22
India business contributes to a stellar performance
Subscribe To Our Newsletter & Stay Updated